SCHEMBL2488081

SCHEMBL2488081

CN(C)c1ccc(C(=O)NC(C)(C)C(=O)Nc2nc(-c3ccccc3)c(Cc3ccccc3)s2)cc1

nearest known ligand 0.50

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PLTP P55058 6/20 0.50
RORC P51449 1/20 0.47
ITK Q08881 1/20 0.45
DGAT1 O75907 2/20 0.44
TRPV4 Q9HBA0 1/20 0.43
ADORA2A P29274 3/20 0.42
ADORA1 P30542 3/20 0.42
ALDH1A1 P00352 3/20 0.41
PTGDR2 Q9Y5Y4 1/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
NPC1 O15118 1/20 0.41
RAB9A P51151 1/20 0.41
KMT2A Q03164 1/20 0.41
ADORA3 P0DMS8 2/20 0.40
HPGD P15428 1/20 0.40
TSHR P16473 1/20 0.40
HSD17B10 Q99714 1/20 0.40
MAPT P10636 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2320700 0.89 PLTP (0.49) PLTPRORCITKDGAT1TRPV4
SCHEMBL2484995 0.88 PLTP (0.51) PLTPRORCDGAT1ADORA2AADORA1
SCHEMBL2485677 0.88 PLTP (0.51) PLTPRORCDGAT1ADORA2AADORA1
SCHEMBL2491014 0.87 ADORA1 (0.55) PLTPRORCDGAT1TRPV4ADORA2A
SCHEMBL2487641 0.85 DGAT1 (0.49) PLTPRORCDGAT1ADORA2AADORA1
SCHEMBL2487360 0.85 DGAT1 (0.63) PLTPRORCDGAT1ADORA2AADORA1
SCHEMBL13531700 0.85 PLTP (0.55) PLTPRORCDGAT1ADORA2AADORA1
SCHEMBL2488862 0.83 LMNA (0.56) PLTPRORCDGAT1ADORA2AADORA1
SCHEMBL2487506 0.83 PLTP (0.52) PLTPRORCDGAT1TRPV4ADORA2A
SCHEMBL2489832 0.83 TRPV4 (0.57) PLTPRORCDGAT1TRPV4ADORA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8703761-B2 Organic compounds NOVARTIS AG (CH) 2014-04-22 US disclosed
EP-2559455-A1 Heteroaryl derivatives as DGAT1 inhibitors Novartis AG (CH) 2013-02-20 EP disclosed
EP-2548618-A2 Organic compounds Novartis AG (CH) 2013-01-23 EP disclosed
EP-2380631-A1 Heteroaryl derivatives as DGAT1 inhibitors Novartis AG (CH) 2011-10-26 EP disclosed
CN-102119047-A Heteroaryl derivatives as DGAT1 inhibitors NOVARTIS AG 2011-07-06 CN disclosed
US-20100022513-A1 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2010-01-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100022513-A1 ORGANIC COMPOUNDS DGAT1, DGAT2, SOAT1 PLTP 575/4885RORC 1166/4885ITK 4450/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.